Tracers / [68Ga]C803-GIP
[68Ga]C803-GIP
Also written as [Ga-68]Ga-C803-GIP
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated GIP/exendin-4 hybrid peptide (GIPR-targeting peptide)
- Target / mechanism
- GIPR (glucose-dependent insulinotropic polypeptide receptor) PMID 36678558
- Clinical application
- PET imaging of GIPR expression, potential in neuroendocrine neoplasms PMID 36678558
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | SPE | 61.1 ± 2.9% no | 94.5 ± 0.3% | C803-GIP Sanofi | 36678558 2022 Pharmaceuticals (Basel) |
Need this precursor?We can point you to suppliers for [68Ga]C803-GIP, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36678558. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.